David R. Bauer
Lawyers
Filters
SSI Strategy acquisition of NDA Group
We advised SSI Strategy on the acquisition
NGM Biopharmaceuticals $100 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Immedica Pharma acquisition of pegzilarginase assets from Aeglea
We advised Immedica on the transaction
BMS $35 million investment in Immatics
We advised Immatics on the private placement of ordinary shares
Korro Bio $117 million private placement
The financing is expected to close immediately prior to the completion of Korro Bio’s merger with Frequency Therapeutics
Centogene strategic collaboration with Lifera
We are advising Centogene on its joint venture with and convertible debt investment by Lifera
Noile-Immune Biotech ¥3.1 billion global IPO
The shares are listed on the Tokyo Stock Exchange
Editas Medicine $125 million follow-on offering
The stock is listed on the Nasdaq Global Select Market
Akoya Biosciences $50 million follow-on offering
The stock is listed on Nasdaq
Ionis Pharmaceuticals $575 million convertible senior notes offering
The 1.75% convertible senior notes are due 2028